Abstract |
Twenty patients with palmoplantar pustulosis (PPP) were treated with topical PUVA, oral etretinate (Re), or combined PUVA and etretinate (Re-PUVA). Re and Re-PUVA treated sites improved and/or cleared more rapidly than PUVA treated sites. Complete clearance was observed in six of ten sites treated with Re-PUVA, two of ten with Re, and one of ten sites with PUVA within 12 weeks. UVA-control sites failed to be cleared within 12 weeks. Remission periods after stopping the treatment were 1.5 +/- 0.5 weeks (n = 2) with Re, 10.5 +/- 11.4 weeks (n = 6) with Re-PUVA, and one year (n = 1) with PUVA. These results overall suggested that Re-PUVA is the most effective treatment for PPP. Tonsillar focal infection (TFI) and dental focal infection (DFI) were found in 6/20 and 17/20 patients, respectively. However, the presence of focal infection (FI), TFI and/or DFI, did not appear to interfere with the therapeutic activities of Re and/or PUVA, because the complete clearance rates and remission periods in FI(+) patients were comparable with those in FI(-) patients.
|
Authors | E Matsunami, A Takashima, N Mizuno, T Jinno, H Ito |
Journal | The Journal of dermatology
(J Dermatol)
Vol. 17
Issue 2
Pg. 92-6
(Feb 1990)
ISSN: 0385-2407 [Print] England |
PMID | 2184179
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)
|
Chemical References |
|
Topics |
- Adult
- Aged
- Drug Therapy, Combination
- Etretinate
(administration & dosage, therapeutic use)
- Female
- Focal Infection
(complications)
- Focal Infection, Dental
(complications)
- Follow-Up Studies
- Humans
- Male
- Middle Aged
- PUVA Therapy
- Palatine Tonsil
- Pharyngeal Diseases
(complications)
- Psoriasis
(complications, drug therapy)
- Randomized Controlled Trials as Topic
|